OPKO Health, Inc. (OPK)
Market Cap | 1.24B |
Revenue (ttm) | 868.08M |
Net Income (ttm) | -209.23M |
Shares Out | 773.06M |
EPS (ttm) | -0.28 |
PE Ratio | n/a |
Forward PE | 64.52 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,186,595 |
Open | 1.57 |
Previous Close | 1.50 |
Day's Range | 1.52 - 1.60 |
52-Week Range | 1.00 - 2.24 |
Beta | 1.76 |
Analysts | Strong Buy |
Price Target | 2.50 (+56.25%) |
Earnings Date | Nov 7, 2023 |
About OPK
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]
Financial Performance
In 2022, OPKO Health's revenue was $1.00 billion, a decrease of -43.42% compared to the previous year's $1.77 billion. Losses were -$328.41 million, 989.5% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for OPK stock is "Strong Buy." The 12-month stock price forecast is $2.5, which is an increase of 56.25% from the latest price.
News

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
Provides Initial $59 Million and up to $168 Million Contingent on Milestones Provides Initial $59 Million and up to $168 Million Contingent on Milestones

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. fi...

OPKO Health is the Little Giant of Diversified Healthcare
Diversified healthcare company OPKO Health Inc. NASDAQ: OPK shares may be low priced, but its businesses pipeline of treatments and upside potential may deserve a higher valuation. Shares trade at 1.6...

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a ...

OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
MIAMI, May 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights i...

OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023
MIAMI, April 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financi...

OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financ...

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings
CINtec ® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, N.J. , Feb. 9, 2023 /PRNewswire/ -- BioReference® Health LLC, one of the largest full-service spec...

OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 03, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41st Annual J.P. Morgan Healthcare Conference being held January 9...

OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

OPKO Health And 2 Other Penny Stocks Are Aggressively Buying - Medalist Diversified REIT (NASDAQ:MDRR), Great Elm Group (NASDAQ:GEG)
US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.

OPKO Health Announces Leadership Changes for BioReference Laboratories
MIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role ...

OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022
MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. fi...

OPKO Health And 2 More Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones surged by more than 800 points on Friday. Investors, meanwhile, focused on some notable insider trades.

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
Transaction to be discussed during OPKO's first quarter 2022 conference call today at 4:30 p.m. ET

11 Stocks Moving Towards A VWAP Breakout: Tellurian, SM Energy, Freshworks And More
Volume-weighted average price or VWAP is the ratio of total volume traded divided by the total volume traded for a chosen time frame. VWAP is an important indicator for intraday trading as it graphica...

GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions
New research underscores the value of sharing genomic information to advance gene matching for diagnosis and discovery GAITHERSBURG, Md., March 16, 2022 /PRNewswire/ -- GeneDx, Inc., a leader in genom...

Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease
ROSWELL, Ga., March 1, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic anal...

OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
Conference call begins at 4:30 p.m. Eastern time today Conference call begins at 4:30 p.m. Eastern time today

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financ...

Pfizer and OPKO's Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation ...

RAYALDEE® Launched in Germany by OPKO Health's Licensee, VFMCRP
MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended re...

Pfizer, Opko Shares Fall After FDA Declines to Approve Somatrogon
Pfizer said it is evaluating the FDA's comments and will work with the agency "to determine an appropriate path forward."

Pfizer - OPKO Health's Growth Hormone Deficiency Candidate Receives FDA Response Letter
The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE) and OPKO Health Inc's (NASDAQ: OPK) somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant huma...